Literature DB >> 26884925

Macroscopic serosal classification of colorectal cancer and its clinical significance.

Yong-Peng Wang1, Peng-Tao Guo2, Zhi Zhu2, Hao Zhang3, Yan Xu2, Si-Ping Ma3, Zhen-Ning Wang2, Hui-Mian Xu2.   

Abstract

BACKGROUND: Macroscopic serosal classification of gastric cancer has been reported in previous studies, but rarely reported about it of colorectal cancer. The purpose of this study was to propose a macroscopic serosal classification of colorectal cancer and to investigate clinical significance of this classification.
MATERIALS AND METHODS: Morphologic features of colorectal cancer were analyzed according to the macroscopic serosal appearance and clinicopathologic characteristics of these patients were retrospectively reviewed. Microscopic serosal structure was compared between different types under light microscope and transmission electron microscope.
RESULTS: Macroscopic serosal classification was divided into normal type, reactive type, nodular type and colloid type according to the macroscopic serosal appearance and microscopic structure. There were significant differences in tumor size, tumor gross type, histological type, histological grade, tumor necrosis, pT stage, number of nodes metastasis, lymph node metastasis ratio, pN stage, M stage and peritoneal metastasis between patients with different serosal types. Univariate analysis of prognosis revealed macroscopic serosal classification as one of factors significantly correlated with patient survival. However, multivariate analysis only revealed TNM stage significantly correlated with patient survival, while macroscopic serosal classification did not, maybe due to insufficient samples.
CONCLUSIONS: Macroscopic serosal classification of colorectal cancer is preliminarily defined and divided into four types. Different macroscopic serosal types indicate different clinicopathologic features and correlate with prognosis of patients with colorectal cancer, but still cannot be proven as an independent factor.

Entities:  

Keywords:  Colorectal cancer; clinicopathologic characteristics; macroscopic serosal classification; prognosis

Year:  2015        PMID: 26884925      PMCID: PMC4723770     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  20 in total

1.  Prognosis of colorectal cancer: clinical, pathological and therapeutic correlation.

Authors:  L Vasile; A Olaru; M Munteanu; I E Pleşea; V Surlin; C Tudoraşcu
Journal:  Rom J Morphol Embryol       Date:  2012       Impact factor: 1.033

2.  Metastatic pattern in colorectal cancer is strongly influenced by histological subtype.

Authors:  N Hugen; C J H van de Velde; J H W de Wilt; I D Nagtegaal
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

3.  Macroscopic serosal classification predicts peritoneal recurrence for patients with gastric cancer underwent potentially curative surgery.

Authors:  Zhe Sun; Ying-ying Xu; Zhen-ning Wang; Zhi Zhu; Hao Zhang; Bao-jun Huang; Yan Xu; Jun-qing Chen; Hui-mian Xu
Journal:  Ann Surg Oncol       Date:  2010-12-14       Impact factor: 5.344

4.  Clinicopathological characteristics of mucinous carcinoma of the colon and rectum.

Authors:  T Nozoe; H Anai; S Nasu; K Sugimachi
Journal:  J Surg Oncol       Date:  2000-10       Impact factor: 3.454

5.  Clinicopathologic characteristics and prognosis of gastric cancer invading the subserosa.

Authors:  Cheng-Gang Jiang; Zhen-Ning Wang; Zhe Sun; Fu-Nan Liu; Miao Yu; Hui-Mian Xu
Journal:  J Surg Oncol       Date:  2010-12-01       Impact factor: 3.454

6.  Colon cancer, version 3.2014.

Authors:  Al B Benson; Alan P Venook; Tanios Bekaii-Saab; Emily Chan; Yi-Jen Chen; Harry S Cooper; Paul F Engstrom; Peter C Enzinger; Moon J Fenton; Charles S Fuchs; Jean L Grem; Steven Hunt; Ahmed Kamel; Lucille A Leong; Edward Lin; Wells Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Eric Rohren; David P Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Kristina M Gregory; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-07       Impact factor: 11.908

7.  Prospective study of peritoneal recurrence after curative surgery for gastric cancer.

Authors:  F Roviello; D Marrelli; G de Manzoni; P Morgagni; A Di Leo; L Saragoni; A De Stefano
Journal:  Br J Surg       Date:  2003-09       Impact factor: 6.939

8.  Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.

Authors:  M Li; J Y Li; A L Zhao; J Gu
Journal:  Oncology       Date:  2008-03-11       Impact factor: 2.935

9.  Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis.

Authors:  Ulrich Nitsche; Anina Zimmermann; Christoph Späth; Tara Müller; Matthias Maak; Tibor Schuster; Julia Slotta-Huspenina; Samuel A Käser; Christoph W Michalski; Klaus-Peter Janssen; Helmut Friess; Robert Rosenberg; Franz G Bader
Journal:  Ann Surg       Date:  2013-11       Impact factor: 12.969

10.  Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study.

Authors:  Sylvain Kirzin; Laetitia Marisa; Rosine Guimbaud; Aurélien De Reynies; Michèle Legrain; Pierre Laurent-Puig; Pierre Cordelier; Bernard Pradère; Delphine Bonnet; Fabienne Meggetto; Guillaume Portier; Pierre Brousset; Janick Selves
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

View more
  2 in total

1.  Macroscopic serosal invasion and small tumor size as independent prognostic factors in stage IIA colon cancer.

Authors:  Soo Young Lee; Chang Hyun Kim; Young Jin Kim; Hyeong Rok Kim
Journal:  Int J Colorectal Dis       Date:  2018-04-28       Impact factor: 2.571

2.  Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).

Authors:  Lin Zhang; Juan Ye; Qiuyun Luo; Miaohuan Kuang; Minjie Mao; Shuqin Dai; Xueping Wang
Journal:  Cancer Manag Res       Date:  2020-07-03       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.